So, working out the fail-safe ways to boost your inner calm is absolutely key at this time of year. That said, what increases ...

YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The ...